Abstracts Archive - Page 2003 of 2616 - ACR Meeting Abstracts

Abstract Number: 1824 • 2015 ACR/ARHP Annual Meeting
Tripterygium Wilfordii for the Treatment of Systemic Lupus Systematosus: Meta-Analysis of Randomized Controlled Trials
Yixia Ye¹, Bo Chen², Robert A. Kalish³ and Chenchen Wang⁴, ¹Rheumatology, Tufts Medical Center, Boston, MA, ²Orthopaedics and Traumatology, Shuguang Hospital affiliated to Shanghai University of T.C.M., Shanghai, China, ³Medicine, Tufts Medical Center, Boston, MA, ⁴Rheumatology, Tufts Medical Center, Bosotn, MA
Background/Purpose: Tripterygium Wilfordii (TPW), a Chinese herbal medication, has been widely used in China for various chronic inflammatory and autoimmune diseases, including systemic lupus erythematosus…
Abstract Number: 1825 • 2015 ACR/ARHP Annual Meeting
Osteoprotegerin Is Associated with Lupus and with Coronary Artery Calcification
Indu Poornima¹, Kelly J. Shields², Susan Manzi³, Rosalind Ramsey-Goldman⁴, Carrie Richardson⁵, Lewis Kuller⁶, George Kondos⁷, James Carr⁵, Craig Langman⁵, Heather Price⁵, Daniel Edmundowicz⁸ and Rachel Mackey⁹, ¹Division of Cardiology, Allegheny Health Network, Pittsburgh, PA, ²Rheumatology, Allegheny Singer Research Institute, Pittsburgh, PA, ³Rheumatology, Allegheny Health Network, Pittsburgh, PA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Evanston, IL, ⁶Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Illinois in Chicago, Chicago, IL, ⁸Cardiology, Temple University School of Medicine, Philadelphia, PA, ⁹Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In the general population, we and others have reported that higher osteoprotegerin (OPG), a protein involved in bone remodeling, is associated with higher levels…
Abstract Number: 1826 • 2015 ACR/ARHP Annual Meeting
Small LDL-P Increases with Increased Disease Activity in SLE
Laura Durcan¹, Deborah Winegar², Margery Connelly², James Otvos², Laurence S Magder³ and Michelle Petri¹, ¹Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ²LabCorp, Raleigh, NC, ³Epidemiology and Preventive Medicine, University of MD, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus (SLE) associates with accelerated atherosclerotic cardiovascular (CV) disease which is not fully explained by traditional CV risk factors. Disease activity, prednisone…
Abstract Number: 1827 • 2015 ACR/ARHP Annual Meeting
Plasma Myeloperoxidase Levels Are Inversely Associated with Carotid Plaque in SLE
Maureen A. McMahon^1,2, Jennifer M. Grossman^3,4,5, Lori Sahakian^6,7, Elaine Lourenco⁸, John FitzGerald^9,10, Christina Charles-Schoeman³, Alan Gorn^3,10, Michael Weisman¹¹, Daniel J Wallace^12,13, Bevra H. Hahn^3,14 and Brian Skaggs³, ¹Div of Rheumatology, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁴Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Rheumatology, UCLA, Los Angeles, CA, ⁶Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁷Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁸UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ⁹Rheumatology, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹⁰Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ¹¹Rheumatology, Cedars-Sinai Medical Center, West Hollywood, CA, ¹²Division of Rheumatology, Cedars-Sinai Medical Center/David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹³Cedars-Sinai Medical Center, West Hollywood, CA, ¹⁴Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA
Background/Purpose: : Women with SLE have increased risk of atherosclerosis (ATH) that is not adequately explained by traditional risk factors. We previously discovered that a…
Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus
Philip Brohawn¹, Lingning Santiago², Chris Morehouse¹, Brandon Higgs¹, Gabor Illei¹ and Koustubh Ranade¹, ¹MedImmune, Gaithersburg, MD, ²MedImmune, Mountain View, CA
Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
Abstract Number: 1829 • 2015 ACR/ARHP Annual Meeting
Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe¹, David Albert⁴, Judith A. James⁵ and Joan T. Merrill³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴AliveCor, Inc., San Francisco, CA, ⁵Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Decreased heart rate variability (HRV), associated with adverse outcomes in cardiovascular diseases, is frequently seen in patients with SLE. The LF/HF ratio, a HRV…
Abstract Number: 1830 • 2015 ACR/ARHP Annual Meeting
Periodontal Disease in Lupus Erythematosus and Cardiovascular Risk Factors
Maria Cecilia Goizueta¹, Luciana Gonzalez Lucero¹, Maria Constanza Bertolaccini², Ramiro Maldonado¹, Raul Sueldo¹, Raul Nicolas Martinez¹, María Silvia Yacuzzi¹, Maximiliano Machado Escobar¹, Mirta Santana¹, Jose Rodriguez Skegro¹, Eugenia fatima del Valle Reynoso¹, Patricia Morales¹, Liliana Galindo¹, Veronica Bellomio¹ and Eleonora Lucero¹, ¹Hospital Angel Cruz Padilla, Tucumán, Argentina, ²Rheumatology, Hospital Angel Cruz Padilla, Tucumán, Argentina
Background/Purpose: The aim of this study was to determine the prevalence of periodontal disease (POD) in patients with Systemic Lupus Erythematosus (SLE) and its relationship with…
Abstract Number: 1831 • 2015 ACR/ARHP Annual Meeting
Initial Risk Factor Profile and Long-Term Cardiovascular Outcome in Women with Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna Gladman², Jiandong Su², Olga Ace³, Arthy Sabapathy³, Anne MacKinnon³ and Murray Urowitz^4,5, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: We previously reported the influence of traditional and disease-related risk factors on the development of cardiovascular disease (CVD) in patients with systemic lupus erythematosus…
Abstract Number: 1832 • 2015 ACR/ARHP Annual Meeting
Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies
Mohammed Attar¹, Jiandong Su², Stacey E. Morrison³, Samar Alharbi⁴, Khawla Al-Ghanim⁵, Dafna Gladman², Murray Urowitz^6,7 and Jorge Sánchez-Guerrero⁸, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada, ⁵Rheumatology, TWH, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Thrombotic events (TE) are common in patients with SLE. Antiphospholipid antibodies (aPL) are a risk factor for incident and recurrent TE; therefore these patients…
Abstract Number: 1833 • 2015 ACR/ARHP Annual Meeting
Musculoskeletal Complications of Systemic Lupus Erythematosus: Risk Factors for and Prevalence of Avascular Necrosis and Osteoporosis
Maeve Gamble¹ and Janet E. Pope², ¹Medicine, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Osteoporosis (OP) and avascular necrosis (AVN) are well-recognized musculoskeletal complications of systemic lupus erythematosus (SLE) and cause morbidity. Steroid therapy and the underlying disease…
Abstract Number: 1834 • 2015 ACR/ARHP Annual Meeting
Total Hip Arthroplasty Outcomes: A 17 Year Experience in a Single-Center: Is Systemic Lupus Erythematosus a Real Risk Factor for Adverse Outcomes?
Marco González-Contreras¹, Javier Merayo-Chalico¹, Rigoberto Ortíz-Hernández², Diana Gómez-Martín² and Jorge Alcocer-Varela², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: In patients with systemic lupus erythematosus (SLE), persistent joint activity and treatment with glucocorticoids are associated with musculoskeletal complications, including hip osteonecrosis. About 30%…
Abstract Number: 1835 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement
Arielle Fein¹, Caroline Figgie¹, Taylor Dodds², Joshua Wright-Chisem³, Michael Parks⁴, Lisa Mandl⁵, Edwin Su⁶, Jane E. Salmon^5,7, David J. Mayman⁴, Yuo-Yu Lee⁸, Mark P. Figgie² and Susan M. Goodman⁷, ¹Research, Hospital for Special Surgery, New York, NY, ²Orthopaedics, Hospital for Special Surgery, New York, NY, ³University of Illinois at Chicago College of Medicine, Chicago, IL, ⁴Orthopedics, Hospital for Special Surgery, New York, NY, ⁵Hospital for Special Surgery, New York, NY, ⁶Orthopedic Surgery, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: More Systemic Lupus Erythematosus (SLE) patients are undergoing total knee arthroplasty (TKA) with equivalent benefits to osteoarthritis (OA) patients. While post-surgical adverse events (AEs)…
Abstract Number: 1836 • 2015 ACR/ARHP Annual Meeting
Standardized Incidence Ratio (SIR), Time Trend and Risk Factors of Avascular Bone Necrosis (AVN) in Patients with Systemic Lupus Erythematosus (SLE)
Sau Mei Tse¹, Chi Chiu Mok¹, Kar Li Chan¹ and Ling Yin Ho², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To study the standardized incidence ratio (SIR), time trend and risk factors of AVN in patients with SLE. Methods: The records of all patients…
Abstract Number: 1837 • 2015 ACR/ARHP Annual Meeting
Predictability of Musculoskeletal Flares and Hand Deformities in Systemic Lupus Erythematosus By High Resolution Ultrasound : 5-Year Clinical and Imaging Prospective Follow-up Study
Matteo Piga¹, Alessandra Gabba¹, Mattia Congia¹, Fabiana Figus¹, Alberto Floris^1,2, Alberto Cauli¹ and Alessandro Mathieu¹, ¹University of Cagliari, Cagliari, Italy, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: SLE patients develop non-deforming non-erosive (NDNE) arthritis in 70-80%, but 5-15% of cases progresses into Jaccoud's arthropathy (JA) a non-erosive deforming arthritis. This study…
Abstract Number: 1838 • 2015 ACR/ARHP Annual Meeting
Joint Ultrasonography May be Useful to Assess Disease Activity in Systemic Lupus Erythematosus (SLE) Patients: A Prospective Multicenter Study
Carine Salliot¹, Emmanuelle Dernis Labous², Aleth Perdriger³, Jean David Albert⁴, Amelie Denis⁵, Saloua Mammou⁶, Isabelle Griffoul⁷, Benoit Le Goff⁸, Sandrine Jousse-Joulin⁹, Christophe Richez¹⁰, Nicolas Poursac¹⁰, Mohamed Hamidou¹¹, Virginie Martaille¹², Antoine Valery¹³ and Emilie Ducourau¹⁴, ¹Rheumatology, CHR Orleans, Orléans, France, ²Réseau Hôpital et Ville en Rhumatologie (RHEVER) Network, Paris, France, ³Service de Rhumatologie, CHU de Rennes, Rennes, France, ⁴Rheumatology Unit, Rennes, France, ⁵Rheumatology, CH Le Mans, Le Mans, France, ⁶Rheumatology, CHU Tours, Tours, France, ⁷Rheumatology, CHU TOURS, Tours, France, ⁸Rheumatology, Nantes University Hospital, Nantes, France, ⁹Rheumatology, CHu La cavle Blanche, Brest, France, ¹⁰Rheumatology, CHU Bordeaux, Bordeaux, France, ¹¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ¹²Rheumatology, CHR Orléans, Orleans, France, ¹³Statistics, CHR Orleans, Orleans, France, ¹⁴Rheumatology, CHR Orleans, Orleans, France
Background/Purpose: Arthritis is a current manifestation of SLE and participates to the SLEDAI composite score calculation (0 to 105). Ultrasonography (US) is a validated and…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].